Trial Outcomes & Findings for Veterans Achieving Weight Loss and Optimizing Resilience-Using Protein (NCT NCT03835416)

NCT ID: NCT03835416

Last Updated: 2025-06-06

Results Overview

SPPB total score is the sum of scores from 3 measures, namely balance, gait speed, and chair stands. Score scale 0-12. Higher numbers indicate higher functioning.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

105 participants

Primary outcome timeframe

0 months

Results posted on

2025-06-06

Participant Flow

Participants were recruited based on medical record queries and letters and at Veteran organizations between September 2019 and October 2023. The first participant was enrolled on 12/12/2019 and the last participant was enrolled on 10/27/2023.

SPPB and A1c or fasting glucose collected after consent were part of eligibility criteria. Of 105 enrolled participants, 64 met inclusion criteria and were randomized in the trial.

Participant milestones

Participant milestones
Measure
WL-Control
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Protein
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Overall Study
STARTED
32
32
Overall Study
COMPLETED
20
25
Overall Study
NOT COMPLETED
12
7

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Veterans Achieving Weight Loss and Optimizing Resilience-Using Protein

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
WL-Control
n=32 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Protein
n=32 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Total
n=64 Participants
Total of all reporting groups
Age, Continuous
69.2 years
STANDARD_DEVIATION 6.9 • n=99 Participants
65.9 years
STANDARD_DEVIATION 6.8 • n=107 Participants
67.6 years
STANDARD_DEVIATION 7.0 • n=206 Participants
Sex: Female, Male
Female
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Sex: Female, Male
Male
32 Participants
n=99 Participants
32 Participants
n=107 Participants
64 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
32 Participants
n=99 Participants
32 Participants
n=107 Participants
64 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
16 Participants
n=99 Participants
16 Participants
n=107 Participants
32 Participants
n=206 Participants
Race (NIH/OMB)
White
16 Participants
n=99 Participants
16 Participants
n=107 Participants
32 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
32 Participants
n=99 Participants
32 Participants
n=107 Participants
64 Participants
n=206 Participants
BMI (kg/m^2)
35.0 kg/m^2
STANDARD_DEVIATION 4.2 • n=99 Participants
36.5 kg/m^2
STANDARD_DEVIATION 4.3 • n=107 Participants
35.8 kg/m^2
STANDARD_DEVIATION 4.3 • n=206 Participants

PRIMARY outcome

Timeframe: 0 months

SPPB total score is the sum of scores from 3 measures, namely balance, gait speed, and chair stands. Score scale 0-12. Higher numbers indicate higher functioning.

Outcome measures

Outcome measures
Measure
WL-Protein
n=32 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=32 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Total Short Physical Performance Battery (SPPB) Score at Baseline
9.6 score on a scale
Standard Deviation 1.2
9.5 score on a scale
Standard Deviation 1.3

PRIMARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

SPPB total score is the sum of scores from 3 measures, namely balance, gait speed, and chair stands. Score scale 0-12. Higher numbers indicate higher functioning. The change score is determined by the value at 3 months minus the value at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=18 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Total Short Physical Performance Battery (SPPB) Score at 3 Months
1.48 score on a scale
Standard Deviation 1.03
1.22 score on a scale
Standard Deviation 1.17

PRIMARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

SPPB total score is the sum of scores from 3 measures, namely balance, gait speed, and chair stands. Score scale 0-12. Higher numbers indicate higher functioning. The change score is determined by the value at 6 months minus the value at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Total Short Physical Performance Battery (SPPB) Score at 6 Months
1.85 score on a scale
Standard Deviation 1.23
1.00 score on a scale
Standard Deviation 1.28

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Body weight was measured on the same scale, with light clothing and no shoes, measured to nearest 0.1 lbs. Percent change in body weight was calculated by subtracting weight at 3 months from weight at baseline, dividing by weight at baseline, and multiplying by 100.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=18 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Percent Change in Body Weight at 3 Months
-4.7 percent change in body weight
Standard Deviation 4.1
-3.1 percent change in body weight
Standard Deviation 3.0

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Body weight was measured on the same scale, with light clothing and no shoes, measured to nearest 0.1 lbs. Percent change in body weight was calculated by subtracting weight at 6 months from weight at baseline, dividing by weight at baseline, and multiplying by 100.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Percent Change in Body Weight at 6 Months
-6.2 percent change of body weight
Standard Deviation 4.7
-6.5 percent change of body weight
Standard Deviation 4.6

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Meters walked in six minutes on a designated course. Change in meters walked was calculated by subtracting meters walked at 3 months from meters walked at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=17 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in 6 Minute Walk Test (Aerobic Endurance) at 3 Months
63.29 meters
Standard Deviation 58.71
34.32 meters
Standard Deviation 49.10

SECONDARY outcome

Timeframe: 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Meters walked in six minutes on a designated course. Change in meters walked was calculated by subtracting meters walked at 6 months from meters walked at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in 6 Minute Walk Test (Aerobic Endurance) at 6 Months
65.90 meters
Standard Deviation 61.57
68.10 meters
Standard Deviation 39.29

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Begins seated. On word 'go' stands, walks around a cone 8 feet away, returns to seated. Timing starts on 'go' and ends when seated. Change in time walked was calculated by subtracting time walked at 3 months from time walked at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=17 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Timed 8-ft Up and Go (Agility/Dynamic Balance) at 3 Months
-1.90 seconds
Standard Deviation 1.96
-1.58 seconds
Standard Deviation 1.29

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Begins seated. On word 'go' stands, walks around a cone 8 feet away, returns to seated. Timing starts on 'go' and ends when seated. Change in time walked was calculated by subtracting time walked at 6 months from time walked at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Timed 8-ft Up and Go (Agility/Dynamic Balance) at 6 Months
-2.12 seconds
Standard Deviation 2.27
-2.10 seconds
Standard Deviation 0.88

SECONDARY outcome

Timeframe: Baseline and 3 months

With arms across chest, stand up completely and return to seated as many times as possible in 30 seconds. Change in number of chair stands was calculated by subtracting number of chair stands at 3 months from number of chair stands at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

With arms across chest, stand up completely and return to seated as many times as possible in 30 seconds. Change in number of chair stands was calculated by subtracting number of chair stands at 6 months from number of chair stands at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Knee extensor at 60 degrees with a dynamometer. Average peak torque for three trials will be recorded. Change in peak torque was calculated by subtracting peak torque at 3 months from peak torque at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=17 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Isokinetic Knee Extension Peak Torque (Muscle Strength) at 3 Months
4.66 newton-meters
Standard Deviation 31.54
-5.02 newton-meters
Standard Deviation 20.65

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Knee extensor at 60 degrees with a dynamometer. Average peak torque for three trials will be recorded. Change in peak torque was calculated by subtracting peak torque at 6 months from peak torque at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Isokinetic Knee Extension Peak Torque (Muscle Strength) at 6 Months
-3.98 newton-meters
Standard Deviation 33.50
-7.20 newton-meters
Standard Deviation 18.92

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Using the Jamar Hand Dynamometer, the amount of pressure placed when squeezing the instrument as hard as possible was measured. Two trials per hand were measured. Change in hand grip was calculated by subtracting the highest value at 3 months from the highest value at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=18 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Isometric Hand Grip (Upper Body Strength) at 3 Months
3.69 kilograms
Standard Deviation 5.61
0.85 kilograms
Standard Deviation 4.32

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Using the Jamar Hand Dynamometer, the amount of pressure placed when squeezing the instrument as hard as possible was measured. Two trials per hand were measured. Change in hand grip was calculated by subtracting the highest value at 6 months from the highest value at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Isometric Hand Grip (Upper Body Strength) at 6 Months
3.01 kilograms
Standard Deviation 6.55
1.21 kilograms
Standard Deviation 5.02

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Minimal waist circumference was measured at smallest horizontal circumference above umbilicus and below xiphoid process. Change in minimal waist circumference was calculated by subtracting the measurement at 3 months from the measurement at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=18 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Minimal Waist Circumference at 3 Months
-4.12 centimeters
Standard Deviation 3.90
-2.64 centimeters
Standard Deviation 3.76

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Minimal waist circumference was measured at smallest horizontal circumference above umbilicus and below xiphoid process. Change in minimal waist circumference was calculated by subtracting the measurement at 6 months from the measurement at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Minimal Waist Circumference at 6 Months
-4.81 centimeters
Standard Deviation 4.30
-4.95 centimeters
Standard Deviation 5.10

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Air displacement plethysmography method (Life Measurement, Inc., Concord, CA). The Cardio Pulmonary, Metabolic and Body Composition (COSMED) BodPod has excellent sensitivity and test-to-test reliability, ease of use, and non-invasive nature, which is important for full participation from this population. Percent lean mass was calculated by the BodPod machine and entered into a REDCap database. Then, change in percent lean mass was calculated by subtracting the percent lean mass at 3 months from the percent lean mass at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=18 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Body Composition: Percent Lean Mass at 3 Months
2.37 change in total lean mass percentage
Standard Deviation 2.37
1.11 change in total lean mass percentage
Standard Deviation 1.57

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Air displacement plethysmography method (Life Measurement, Inc., Concord, CA). The Cardio Pulmonary, Metabolic and Body Composition (COSMED) BodPod has excellent sensitivity and test-to-test reliability, ease of use, and non-invasive nature, which is important for full participation from this population. Percent lean mass was calculated by the BodPod machine and entered into a REDCap database. Then, change in percent lean mass was calculated by subtracting the percent lean mass at 6 months from the percent lean mass at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Body Composition: Percent Lean Mass at 6 Months
3.31 change in total lean mass percentage
Standard Deviation 2.77
2.95 change in total lean mass percentage
Standard Deviation 2.94

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Air displacement plethysmography method (Life Measurement, Inc., Concord, CA). The Cardio Pulmonary, Metabolic and Body Composition (COSMED) BodPod has excellent sensitivity and test-to-test reliability, ease of use, and non-invasive nature, which is important for full participation from this population. Percent fat mass was calculated by the BodPod machine and entered into a REDCap database. Then, change in percent fat mass was calculated by subtracting the percent fat mass at 3 months from the percent fat mass at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=21 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=18 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Body Composition: Percent Fat Mass at 3 Months
-2.37 change in total body fat mass percentage
Standard Deviation 2.37
-1.11 change in total body fat mass percentage
Standard Deviation 1.57

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Air displacement plethysmography method (Life Measurement, Inc., Concord, CA). The Cardio Pulmonary, Metabolic and Body Composition (COSMED) BodPod has excellent sensitivity and test-to-test reliability, ease of use, and non-invasive nature, which is important for full participation from this population. Percent fat mass was calculated by the BodPod machine and entered into a REDCap database. Then, change in percent fat mass was calculated by subtracting the percent fat mass at 6 months from the percent fat mass at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=20 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=12 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Body Composition: Percent Fat Mass at 6 Months
-3.31 change in total body fat mass percentage
Standard Deviation 2.77
-2.95 change in total body fat mass percentage
Standard Deviation 2.94

SECONDARY outcome

Timeframe: Baseline only

To assess for cognitive impairment, the mini cog was used to screen for eligibility at baseline only. The mini cog includes two components - a 3-item recall and a clock drawing. You can score 0-3 points for the 3-item recall, and 0-2 points for the clock drawing. These subscale scores are summed for a total possible score of 5. Subscale scores were not reported, only the total score. The total score is a range of 0-5. The max total score is 5 with 5 being the best score. To be eligible for the study, the total item recall and clock score needed to be 3 or higher.

Outcome measures

Outcome measures
Measure
WL-Protein
n=32 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=32 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Mini-Cog at Baseline Only
4.06 score on a scale
Standard Deviation 0.98
3.97 score on a scale
Standard Deviation 0.90

SECONDARY outcome

Timeframe: Baseline and 3 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Cross sectional area of the thigh to determine thigh muscle mass. Change in area calculated by subtracting area at 3 months from area at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=19 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=22 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Computerized Axial Tomography (CAT) Scan at 3 Months
4.65 cm^2
Standard Deviation 18.76
1.68 cm^2
Standard Deviation 16.79

SECONDARY outcome

Timeframe: Baseline and 6 months

Population: A small number of participants do not have this measurement due to COVID-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Cross sectional area of the thigh to determine thigh muscle mass. Change in area calculated by subtracting area at 6 Months from area at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=10 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=14 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Change in Computerized Axial Tomography (CAT) Scan at 6 Months
2.43 cm^2
Standard Deviation 13.95
7.22 cm^2
Standard Deviation 22.20

SECONDARY outcome

Timeframe: Baseline and 3 months

Quality of Life Questionnaires The SF-36 measures 8 QOL domains which are dichotomized into physical (functioning, role limitations-physical, pain, general health) and mental health (vitality, social functioning, role limitations-emotional, and emotional/mental health). Item scores were converted to a 0-100 point scale; domain scores were derived by averaging individual items within the subscale; and physical composite and mental health composite scores were derived by averaging the four component domains of each. Higher values are indicative of better QOL. Change in score calculated by subtracting score at 3 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Quality of Life Questionnaires The SF-36 measures 8 QOL domains which are dichotomized into physical (functioning, role limitations-physical, pain, general health) and mental health (vitality, social functioning, role limitations-emotional, and emotional/mental health). Item scores were converted to a 0-100 point scale; domain scores were derived by averaging individual items within the subscale; and physical composite and mental health composite scores were derived by averaging the four component domains of each. Higher values are indicative of better QOL. Change in score calculated by subtracting score at 6 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Mood Questionnaires The 30-item POMS measures mood and mood changes, has low respondent burden, and includes 6 subscales: tension, depression, anger, fatigue, confusion and vigor (all with range 0-20). Total mood disturbance (TMD) is derived from POMS using the following formula, TMD = (Sum of all subscales except vigor) - vigor (range -20 - 100). Change in score calculated by subtracting score at 3 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Mood Questionnaires The 30-item POMS measures mood and mood changes, has low respondent burden, and includes 6 subscales: tension, depression, anger, fatigue, confusion and vigor (all with range 0-20). Total mood disturbance (TMD) is derived from POMS using the following formula, TMD = (Sum of all subscales except vigor) - vigor (range -20 - 100). Change in score calculated by subtracting score at 6 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Depression Questionnaires Individuals were coded as positive for depression if they had a CES-D score of 16 and/or had self-report of depression diagnosis at baseline. In addition to the total score, the CES-D includes 4 subscales: depressed affect (range 0-21), positive affect (range 0-12), somatic (range 0-21), and interpersonal (range 0-6). Change in score calculated by subtracting score at 3 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Depression Questionnaires Individuals were coded as positive for depression if they had a CES-D score of 16 and/or had self-report of depression diagnosis at baseline. In addition to the total score, the CES-D includes 4 subscales: depressed affect (range 0-21), positive affect (range 0-12), somatic (range 0-21), and interpersonal (range 0-6). Change in score calculated by subtracting score at 6 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Stress Questionnaires The PSS assesses the degree to which situations in one's life are considered stressful (range 0-40). Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress. Change in score calculated by subtracting score at 3 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Stress Questionnaires The PSS assesses the degree to which situations in one's life are considered stressful (range 0-40). Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress. Change in score calculated by subtracting score at 6 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Quality of sleep Questionnaires Reported PSQI values include only these six component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, and use of sleeping medication (all with a range 0-3). The PSQI includes a scoring key for calculating a patient's seven subscores, each of which can range from 0 to 3. The subscores are tallied, yielding a "global" score that can range from 0 to 21. A global score of 5 or more indicates poor sleep quality; the higher the score, the worse the quality. Change in score calculated by subtracting score at 3 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Quality of sleep Questionnaires Reported PSQI values include only these six component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, and use of sleeping medication (all with a range 0-3). The PSQI includes a scoring key for calculating a patient's seven subscores, each of which can range from 0 to 3. The subscores are tallied, yielding a "global" score that can range from 0 to 21. A global score of 5 or more indicates poor sleep quality; the higher the score, the worse the quality. Change in score calculated by subtracting score at 6 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Life Satisfaction Questionnaires The SWLS evaluates global life satisfaction, an important component of subjective well-being (range 5-35). The SWLS is a 7-point Likert scale style response scale. The possible range of scores is 5-35, with a score of 20 representing a neutral point on the scale. Scores between 5-9 indicate the respondent is extremely dissatisfied with life, whereas scores between 31-35 indicate the respondent is extremely satisfied. Change in score calculated by subtracting score at 3 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Life Satisfaction Questionnaires The SWLS evaluates global life satisfaction, an important component of subjective well-being (range 5-35). The SWLS is a 7-point Likert scale style response scale. The possible range of scores is 5-35, with a score of 20 representing a neutral point on the scale. Scores between 5-9 indicate the respondent is extremely dissatisfied with life, whereas scores between 31-35 indicate the respondent is extremely satisfied. Change in score calculated by subtracting score at 6 months from score at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Blood assay (LabCorp). Change in value calculated by subtracting value at 3 months from value at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Blood assay (LabCorp). Change in value calculated by subtracting value at 6 months from value at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

"Yes" responses to the question, "Do you have a fear of falling?" Change in number of "yes" answers from baseline to 3 months. Change was calculated by subtracting the number of "yes" answers at 3 months from the number of "yes" answers at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

"Yes" responses to the question, "Do you have a fear of falling?" Change in number of "yes" answers from baseline to 6 months. Change was calculated by subtracting the number of "yes" answers at 6 months from the number of "yes" answers at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

This is an open-ended questionnaire to see the change in number of times a person falls between time points. Change in value calculated by subtracting value at 3 months from value at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

This is an open-ended questionnaire to see the change in number of times a person falls between time points. Change in value calculated by subtracting value at 6 months from value at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

3-day diet record by multiple pass; analyzed Food Processor (Version 10.13, 2013; ESHA Research). Change in calories calculated by subtracting average daily calories at 3 months from average daily calories at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

3-day diet record by multiple pass; analyzed Food Processor (Version 10.13, 2013; ESHA Research). Change in calories calculated by subtracting average daily calories at 6 months from average daily calories at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

3-day diet record by multiple pass; analyzed Food Processor (Version 10.13, 2013; ESHA Research). Change in protein in grams calculated by subtracting average daily protein in grams at 3 months from average daily protein in grams at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

3-day diet record by multiple pass; analyzed Food Processor (Version 10.13, 2013; ESHA Research). Change in protein in grams calculated by subtracting average daily protein in grams at 6 months from average daily protein in grams at baseline.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline

Actigraph WGT3X-BT is a wearable accelerometer that measures activity counts, step counts, and physical activity intensity. This outcome is the number of participants who participated in this measurement at baseline.

Outcome measures

Outcome measures
Measure
WL-Protein
n=32 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=32 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Number of Participants Measured Using an Axis Accelerometer (Actigraph)
32 Participants
32 Participants

SECONDARY outcome

Timeframe: 3 months

Population: A small number of participants do not have this measurement due to Covid-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts.

Actigraph WGT3X-BT is a wearable accelerometer that measures activity counts, step counts, and physical activity intensity. This outcome is the number of participants who participated in this measurement at 3 months.

Outcome measures

Outcome measures
Measure
WL-Protein
n=32 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=32 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Number of Participants Measured Using an Axis Accelerometer (Actigraph)
21 Participants
17 Participants

SECONDARY outcome

Timeframe: 6 months

Population: A small number of participants do not have this measurement due to Covid-19 disruptions to clinical research, missed appointments, or participant withdrawals/dropouts. Additionally, some study participants were enrolled for a 3 month, rather than a 6 month, intervention period, thus they have no measurements at 6 months.

Actigraph WGT3X-BT is a wearable accelerometer that measures activity counts, step counts, and physical activity intensity. This outcome is the number of participants who participated in this measurement at 6 months.

Outcome measures

Outcome measures
Measure
WL-Protein
n=32 Participants
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Control
n=32 Participants
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Number of Participants Measured Using an Axis Accelerometer (Actigraph)
20 Participants
12 Participants

SECONDARY outcome

Timeframe: 3 months

Population: These data were unable to be collected due to methodologic difficulties and logistical constraints.

Ingestion of a 75 g glucose load

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Population: These data were unable to be collected due to methodologic difficulties and logistical constraints.

Ingestion of a 75 g glucose load

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 3 months

Attendance counted if in person or virtual. Percentage calculated by dividing number of classes attended by number of classes held and multiplying by 100.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 6 months

Attendance counted if in person or virtual. Percentage calculated by dividing number of classes attended by number of classes held and multiplying by 100.

Outcome measures

Outcome data not reported

Adverse Events

WL-Control

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

WL-Protein

Serious events: 1 serious events
Other events: 13 other events
Deaths: 1 deaths

Consented, Not Randomized

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
WL-Control
n=32 participants at risk
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Protein
n=32 participants at risk
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Consented, Not Randomized
n=41 participants at risk
Participants who consented but were never randomized due to participant withdrawal or not qualifying.
Respiratory, thoracic and mediastinal disorders
Death
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months

Other adverse events

Other adverse events
Measure
WL-Control
n=32 participants at risk
0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
WL-Protein
n=32 participants at risk
\>30 g of high quality protein per meal, 1.4 g protein/kg body weight/day. 21 servings of high quality (30 g/serving) protein (lean meats, whey protein powder, protein drinks) provided to participants each week to increase compliance. Foods rich in high quality protein: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Consented, Not Randomized
n=41 participants at risk
Participants who consented but were never randomized due to participant withdrawal or not qualifying.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder tumor
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Cardiac disorders
Atrial Fibrillation
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Skin and subcutaneous tissue disorders
Surgery
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Injury, poisoning and procedural complications
Broken bone
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
6.2%
2/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Musculoskeletal and connective tissue disorders
Spinal stenosis
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Surgical and medical procedures
Spinal Stenosis
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Respiratory, thoracic and mediastinal disorders
Complications from Pulmonary Fibrosis
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • Number of events 2 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Renal and urinary disorders
Frequent Urination
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Infections and infestations
Respiratory Illness
9.4%
3/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
General disorders
Dizziness, nausea, abdominal pain
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
6.2%
2/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
2.4%
1/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Injury, poisoning and procedural complications
Shoulder pain
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Gastrointestinal disorders
Diarrhea
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
9.4%
3/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Gastrointestinal disorders
Constipation
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Surgical and medical procedures
Adrenal gland removal
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
2.4%
1/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Surgical and medical procedures
Shoulder surgery
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Eye disorders
Eye pain
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Musculoskeletal and connective tissue disorders
Leg pain/weakness
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Vascular disorders
Elevated blood pressure
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
General disorders
ED visit for difficulty breathing/coughing blood possibly related to congestive heart failure
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Infections and infestations
Shingles
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Injury, poisoning and procedural complications
Muscle strain
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Injury, poisoning and procedural complications
Bursitis in elbow
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Injury, poisoning and procedural complications
Blood clot in eye
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
Infections and infestations
Gluteal cleft abscess
3.1%
1/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
0.00%
0/32 • From time of consent to completion of either 3 month or 6 month study, 4-7 months
2.4%
1/41 • From time of consent to completion of either 3 month or 6 month study, 4-7 months

Additional Information

Dr. Connie Bales, Assoc. Director, GRECC

Durham VA Medical Center

Phone: 919-286-0411

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place